PALO ALTO, Calif., November 2, 2016 – NuMedii, Inc. today announced that it is the recipient of the 2016 BioProcess International Emerging Company Award. The event was held in Boston, MA in October 5, 2016 as part of Biotech Week Boston.
“We are pleased to be acknowledged for our Company’s contributions to help discover new uses for medicines that will ultimately benefit patients in need,” said Gini Deshpande, Ph.D., chief executive officer, “Receiving the BioProcess International award for Best Emerging Company underscores our efforts to revolutionize drug discovery by translating big data into pipeline drug candidates with a higher probability of success.”
About NuMedii, Inc.
NuMedii, Inc., discovers effective new drugs by translating its predictive data intelligence technology into therapies with a higher probability of therapeutic success. The Company’s exclusive Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. NuMedii translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. Headquartered in Palo Alto, California, the company’s investors include Claremont Creek Ventures and Lightspeed Venture Partners. For more information, please visit www.numedii.com.
For media inquiries:
For all other inquiries: